Involvement of both dopaminergic and alpha-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN.

doi:10.1016/0014-2999(81)90365-4

Paper

DOI: 10.1016/0014-2999(81)90365-4

Involvement of both dopaminergic and alpha-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN.

Published Apr 9, 1981 · C. Sumners, J. D. de Vries, D. Dijkstra

European journal of pharmacology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

DB-6,7-ADTN induces hypomotility in animals, which can be attenuated by dopamine receptor antagonists and alpha-adrenergic blockers.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/0014-2999(80)90024-2

Activation of presynaptic alpha-noradrenaline receptors in rat brain by the potent dopamine-mimetic N,N-dipropyl-5,6-ADTN.

N,N-dipropyl-5,6-ADTN, a potent dopamine-mimetic, also stimulates presynaptic alpha-noradrenaline receptors in the rat brain.

1980·14citations·A. H. Mulder et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0014-2999(80)90239-3

The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.

COMT activity significantly influences the metabolism of 6,7-ADTN, affecting its concentration in brain and serum, impacting the design of new dopamine agonists.

1980·29citations·H. Rollema et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0014-2999(80)90376-3

Dopaminergic prodrugs: brain concentrations and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters.

The active conformation of dopamine is closer to the -rotamer than the -rotamer, with 6,7-ADTN being 12-14 times more potent than the 5,6-derivative at the receptor site.

1980·31citations·B. Westerink et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0014-2999(79)90056-6

A prodrug of ADTN: selectivity of dopaminergic action and brain levels of ADTN.

The prodrug dibenzoyl ADTN selectively arouses dopamine in the corpus striatum, with slow onset and long duration, potentially aiding in designing new selectively acting DA agonists.

1979·16citations·A. Horn et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1126/SCIENCE.482929

Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists.

Dopamine auto- and postsynaptic receptors show differential sensitivity to agonists, potentially explaining paradoxical behavioral effects and providing a basis for developing new drugs to antagonize dopaminergic influence in the central nervous system.

1979·511citations·L. Skirboll et al.·Science

Science

DOI: 10.1111/j.1476-5381.1979.tb07848.x

HYPERPOLARIZING ‘α2’‐ADRENOCEPTORS IN RAT SYMPATHETIC GANGLIA

Catecholamine-induced hyperpolarization in rat sympathetic ganglia occurs solely through activation of '2'-receptors, not receptors or dopamine-receptors.

1979·133citations·David A. Brown et al.·British Journal of Pharmacology

British Journal of Pharmacology

DOI: 10.1038/276405A0

A new dopaminergic prodrug

A simplified four-step synthesis of ADTN, a potent and long-acting dopamine agonist, allows for its passage into the brain, potentially improving Parkinson's treatment.

1978·27citations·A. Horn et al.·Nature

Nature

DOI: 10.1021/JM00206A023

Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.

Facile syntheses of potent dopaminergic argonists, 11, 12, and their effects on neurotransmitter release show the importance of catechol function in this uptake-release process.

1978·44citations·A. Horn et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

Citations

DOI: 10.1016/S0031-6989(88)80720-3

Imidazole and yohimbine antagonize hypomotility, penile erection, stretching and yawning induced in rats by BHT 920, a selective dopamine autoreceptor agonist.

Imidazole and yohimbine effectively antagonize the behavioral effects of BHT 920, a selective dopamine autoreceptor agonist, in rats.

1988·3citations·F. Ferrari et al.·Pharmacological research communications

Pharmacological research communications

DOI: 10.1016/0014-2999(88)90783-2

N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.

N-0437 is a selective dopamine D-2 agonist, making it a promising new ligand for studies on this receptor.

1988·42citations·J. van der Weide et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0028-3908(86)90194-2

Electrophysiological effects of the enantiomers of 3-PPP on neurons in the locus coeruleus of the rat

(+)-3-PPP weakly activates alpha 2-adrenoceptors in the locus coeruleus, while ()-3-PPP weakly inhibits them, possibly due to enhanced release of noradrenaline.

1986·22citations·M. Elam et al.·Neuropharmacology

Neuropharmacology

DOI: 10.1016/0014-2999(86)90037-3

Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.

N-0437 shows the most promise as a potential therapeutic candidate due to its long duration of action and high oral activity, while all three compounds are potent and selective dopamine receptor agonists.

1986·69citations·J. van der Weide et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0014-2999(85)90424-8

N-methyl,N-propargyl-2-aminotetralins:novel dopamine agonists with monoamine oxidase inhibiting properties.

Both mono- and dihydroxylated N-methyl,N-propargyl-2-aminotetralins have MAO inhibiting and dopamine agonistic activities, with the monohydroxy structures showing more MAO inhibitory activity.

1985·0citations·B. Hazelhoff et al.·European journal of pharmacology

European journal of pharmacology